Telehealth In The Media

This study is a 12-month, observational, non-interventional study assessing biomarkers, clinical outcomes, and treatment-responsiveness in patients with prurigo nodularis (PN).Patients must be 18 years or older with a confirmed diagnosis of PN (with predominantly nodular disease) by the PI. They must be able to read and understand the consent form and outcomes questionnaires and willing and able to sign the consent form. A separate consent form will be used for genomics testing, which is encouraged for all study participants but not required. Lastly, patients must be willing to participate in the following study-related activities:1) Completion of outcome questionnaires2) Actigraphy data collection3) Biomarker collection by blood draws at each monthly study visit4) Skin biopsy collection5) Medical photography (8-24 photos taken each visit)

Dermatology at The GW Medical Faculty Associates is conducting an experimental research study to examine the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in treating rosacea. The purpose of this study is to evaluate if using 5-ALA PDT improves rosacea symptoms. We are seeking individuals with rosacea between the ages of 18 and 79 to volunteer to participate in this study. This study will take a total of six months (six total visits to the MFA). Prior to each visit, you will be examined and fill out a questionnaire. Participation in the study will be of no direct cost to you. If you are interested in participating in this research study, please contact Dermatology atThe GW Medical Faculty Associates.

The goal of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis (AD). The dose-response of lebrikizumab in patients will also be measured. Patients with moderate-to-severe AD will be enrolled into this 32-week study. Patients will be seen every 2 weeks, will receive all study drug injections in the clinic, and be evaluated for safety and efficacy through Week 16. A safety follow-up visit will occur at Week 24 and a follow-up phone call will occur at Week 32.

The goal of this study is to evaluate the efficacy and safety of baricitinib 1-mg daily and 2-mg daily in comparison to placebo in adult patients with moderate to severe atopic dermatitis. The study is divided into 3 periods: a 5-week Screening Period, a 104-week Double-Blinded Treatment Period, and a 4-week Post-Treatment Follow-Up Period.

The goal of this study is to evaluate the efficacy of BIIB059 in reducing disease activity in subjects with active cutaneous lupus erythematosus (CLE). The subject screening period will last up to 4 weeks. This will be followed by a treatment period of 16 weeks, with subjects randomized to 1 of 4 possible arms, all which will receive monthly treatments given in the office. Two groups will receive BIIB059 and two groups will receive the placebo. The following safety follow-up period will consist of 12 weeks of monthly visits.

The GW Medical Faculty Associates Department of Dermatology is conducting an experimental research study to assess collagen powder in treating acute wounds. The purpose of this study is to see if Nuvagen‚Ñ¢ (collagen powder) is effective in treating skin punch biopsy wounds. We are seeking healthy individuals between ages 18-75 to volunteer to participate in this study. The study will take a total of 12 weeks, including 6 total visits to the dermatology clinic. You will receive 1 punch biopsy on each thigh at the 1st and 4th visits. You will also be asked questions about your medical history, answer surveys, and have photographs taken. Participation in the study will be of no direct cost to you.